Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases.
Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases.
复制标题
DOI：
10.1159/000513002
复制
发表时间：
2021-01
影响因子：
0.8
通讯作者：
Saito M
中科院分区：
文献类型：
--
作者：
Ito M;Horimoto Y;Sasaki R;Miyazaki S;Orihata G;Saito M
帕妥珠单抗是一种人源化抗体药物，当与曲妥珠单抗和其他化疗药物联合给药时，可改善人表皮生长因子受体2（HER2）阳性乳腺癌患者的结局。曲妥珠单抗引起的药物毒性已被广泛认可，而在日常临床实践中缺乏基于帕妥珠单抗的治疗数据。我们在此报告了2例日本患者，年龄分别为72岁和49岁，在长期曲妥珠单抗治疗后，帕妥珠单抗给药后发生左心室功能障碍。两名患者均接受了HER2阳性乳腺癌的根治性手术，并接受了基于蒽环类药物的治疗。发生转移性疾病后，给予基于曲妥珠单抗的治疗，无心脏毒性，但2例患者在帕妥珠单抗给药后发生左心室功能障碍（分别为6和13个周期）。尽管几项大型随机试验显示帕妥珠单抗对心功能不全没有累加效应，但在日常实践中仔细监测心功能似乎是必要的，特别是对于既往长期曲妥珠单抗治疗的患者。
Pertuzumab, a humanized antibody drug, has improved outcomes of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer, when administered in combination with trastuzumab and other chemotherapies. Cardiotoxicity due to trastuzumab is widely recognized, while data on pertuzumab-based treatments in daily clinical practice are lacking. We herein report 2 Japanese patients, aged 72 and 49 years, who developed left ventricular dysfunction after pertuzumab administration, following long-term trastuzumab treatments. Both patients underwent curative surgery for their HER2-positive breast cancer and received anthracycline-based treatments. After developing metastatic disease, trastuzumab-based treatments were administered without cardiac toxicity, but both patients developed left ventricular dysfunction after pertuzumab administration (6 and 13 cycles, respectively). Although several large randomized trials have shown no additive effect of pertuzumab on cardiac dysfunction, careful monitoring of cardiac function appears to be necessary in daily practice, particularly for patients with prior long-term trastuzumab treatments.
登录
查看更多内容
影响因子：
1.6
作者：
Jawa Z;Perez RM;Garlie L;Singh M;Qamar R;Khandheria BK;Jahangir A;Shi Y
通讯作者：
Shi Y
影响因子：
9.5
作者：
Vermeulen Z;Segers VF;De Keulenaer GW
通讯作者：
De Keulenaer GW
影响因子：
28.4
作者：
Shao, Zhimin;Pang, Da;Eng-Wong, Jennifer
通讯作者：
Eng-Wong, Jennifer
影响因子：
51.1
作者：
Swain, Sandra M.;Miles, David;Cortes, Javier
通讯作者：
Cortes, Javier
DOI：
10.1056/nejmoa1703643
发表时间：
2017-07-13
期刊：
The New England journal of medicine
影响因子：
--
作者：
von Minckwitz G;Procter M;de Azambuja E;Zardavas D;Benyunes M;Viale G;Suter T;Arahmani A;Rouchet N;Clark E;Knott A;Lang I;Levy C;Yardley DA;Bines J;Gelber RD;Piccart M;Baselga J;APHINITY Steering Committee and Investigators
通讯作者：
APHINITY Steering Committee and Investigators